AKT1 and esophageal cancer: Furthermore, given the molecular mechanism by which SOX9 activates the PI3K/AKT/mTOR signaling pathway in esophageal cancer, the highly expressed SOX9 is a potential indicator for a subset of esophageal cancer patients who are more responsive to rapamycin, a specific mTOR inhibitor that has been used clinically [164].